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Summary We have reviewed the records of the 16,564 cases of childhood cancer diagnosed from 1971 to 1983 which were reported to the National Registry of Childhood Tumours in Great Britain for the presence of
underlying genetic disease in order to estimate the proportion which results from inherited mutations. A genetic condition was listed for 509 patients, or 3.07% of the total number of tumours. The most frequently
recorded diagnoses were: bilateral retinoblastoma (162 cases); Down syndrome (135); neurofibromatosis (90); hereditary Wilms' tumour (71); and tuberous sclerosis (20). The highest hereditary fractions at individual
tumour sites were seen for: retinoblastoma (37.2%); kidney (7.2%); leukaemia (2.6%) and brain and spinal
cord (2.0%). When information about family history from published reports was incorporated into the figures calculated from Registry data the total genetic fraction was estimated to be 4.2%. We conclude that there is a clear genetic basis for a small minority of the cancers ofchildhood, but ethnic variation and the lack of known
environmental determinants suggest that the total influence of heredity may be higher.
A subgroup of cases of childhood cancer are due to inherited
genetic mutations - either transmitted from a carrier parent
or arising de novo in a parental germ cell. On occasion such
mutations are detectable by cytogenetic examination, but for
the great majority, the hereditary nature of cancer is inferred
from inspection of the patient's pedigree or from some
unusual feature of the clinical presentation. The child's
family may carry a predisposing genetic trait (e.g. neurofibro-
matosis or ataxia-telangiectasia) or may reveal an excess
number of cancers in a Mendelian pattern. It has been
suggested that the presence of bilateral tumours in childhood
indicates genetic susceptibility (Knudson et al., 1973), a
hypothesis confirmed for retinoblastoma by the rate of
appearance of these tumours in offspring. The association in
a child of a cancer and particular congenital malformations,
most notably aniridia or hemihypertrophy, may signal the
presence of an underlying mutation.
Current theory proposes that a sequence of genetic muta-
tions leads to the formation of a cancer cell with the capacity
for uncontrolled growth. Should one or more of the muta-
tions in the sequence be present at conception, or should an
individual be liable to an elevated rate of chromosome
breakage or lack an effective DNA repair mechanism, the
risk of cancer is likely to be elevated. If such a trait is shared
by several members of a pedigree, familial clustering may
occur.
Non-genetic explanations for the appearance of multiple
tumours in a family include exposure to a common environ-
mental hazard and chance. An individual treated for an
initial tumour may be at high risk for a second because of
innate susceptibility or because of the mutagenic effects of
anti-neoplastic treatment.
Harmful aspects of the environment have been implicated
as causing perhaps 70% of all cancer (Doll & Peto, 1981) but
because of the lesser variability in incidence seen from
country to country for the common neoplasms of childhood
(Parkin et al., 1988), and because familial cancers tend to
appear at younger ages than isolated cases, it is reasonable to
inquire whether heredity plays a primary role in the etiology
of cancer in children. We have reviewed all cases of cancer
reported to the population-based National Registry of Child-
hood Tumours in Great Britain for a 13-year period in an
attempt to estimate the proportion of childhood cancer due
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to inherited conditions. A case is considered to be hereditary
if an affected child carries a constitutional genetic mutation
(either chromosomal or involving a single gene) which is
associated with a significantly elevated risk for the particular
tumour. We believe that these estimates will help to clarify
the relative magnitude to the influences of hereditary and of
the environment on early onset cancer and will enable inves-
tigators to better formulate hypotheses about the timing of
potential childhood carcinogens and their possible
mechanisms of action.
Material and methods
We have reviewed the 16,564 cases of childhood cancer diag-
nosed during 1971-83 and reported to the National Registry
of Childhood Tumours for the presence ofunderlying genetic
disease. The Registry receives copies of all notifications for
children under age 15 who are reported to national cancer
registration schemes in England, Scotland and Wales.
Confirmation of diagnosis is subsequently obtained from the
hospitals at which the children are treated, from their family doctors or from organisers of clinical trials. Included are all
malignant neoplasms and all other tumours of the brain and
spinal cord, classified according to the scheme of Birch and
Marsden (1987) with the following modifications: (1) Acute
megakaryocytic leukaemia is included with acute non-lymph-
ocytic leukaemia; (2) Non-Hodgkin, Burkitt's and unspecified
lymphoma are combined; (3) Intracranial primitive neuroec-
todermal tumours is classified with medulloblastoma; (4)
'Other glioma' and miscellaneous intracranial and intraspinal
neoplasms are combined; (5) Peripheral neuroectodermal
tumours are included with other sympathetic nervous system
tumours; (6) Rhabdoid renal tumour and clear-cell sarcoma
of kidney are classified with Wilms' tumour. Incidence rates
from the Registry for 1971-1980 and a description of
methods have been published previously (Draper et al., 1988; Stiller et al., 1988).
Information on congenital malformations was requested at
the time the diagnosis was confirmed for all except a small
proportion ofregistrations during 1971-1977 (accounting for
less than 6% of the total). Data on underlying conditions for
skin tumours are generally felt to be incomplete. Laterality is
recorded for most solid tumours, including retinoblastoma
and Wilms' tumour, but not for neuroblastoma. The diag-
nosis of Down syndrome was not routinely verified through
cytogenetics, and, excepting the two cases of 46,XY gonadal
dysgenesis, information on karyotype was not generally
available.
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Cases considered to have a hereditary basis include: (1) all
bilateral retinoblastomas and Wilms' tumours; (2) all child-
ren for which an established underlying genetic condition had
been recorded; and (3) all tumours occurring in children with
aniridia or hemihypertrophy. Excluded were cases with a
history of a congenital malformation not specifically known
to be associated with a defined genetic syndrome.
Information about family history was not routinely avail-
able, but was provided for some tumour types, including
medullary carcinoma of the thyroid. Genetic cancer syn-
dromes diagnosed on the basis of multiple primary tumours
or the appearance of a subsequent benign manifestation of
the syndrome will often be missed in the present analysis.
The relative risk for developing cancer was calculated by
dividing the observed number of hereditary cancer cases by
the expected number. The expected number was the product
of the prevalence of the genetic condition taken from pub-
lished reports and the total number of tumour registrations.
The (two-sided) P-values and confidence limits associated
with risk estimates were calculated assuming a Poisson dis-
tribution of the observed number of cases.
Results
Of the total number of tumours reported, 509 or 3.07% had
an underlying genetic condition recorded, the frequencies of
which appear in Table I. The proportions of particular
tumour types with genetic diagnoses are presented in Table
II.
Bilateral retinoblastoma accounted for one-third of the
genetic total; the median age at diagnosis of 162 bilateral
tumours was 7 months, as compared to 25 months for
unilateral tumours (P<0.001).
Down syndrome was the second most frequently cited
condition. Of the 131 associated leukaemias 73 were acute
lymphocytic, 49 were acute non-lymphocytic, one was chron-
ic myelocytic and eight were classified as other, or unspecified
leukaemia. A higher proportion of cases of acute non-
lymphocytic leukaemia (5.3%) were attributable to Down
syndrome than were acute lymphocytic leukaemias (1.7%).
The relative risk for acute lymphocytic leukaemia was con-
stant at different ages, in contrast to the acute non-lympho-
cytic subtype, where the greatest risk was seen before age 5
(Figure 1). There were three lymphomas associated with
Down syndrome, including one in a phenotypic female with a
Table I Genetic conditions listed in National Registry for Childhood
Tumours
Bilateral retinoblastoma
Down syndrome
Neurofibromatosis
Wilms' tumoura
Tuberous sclerosis
Ataxia-telangiectasia
Multiple endocrine neoplasia
Wiskott-Aldrich syndrome
Beckwith-Wiedemann syndromeb
Fanconi anaemia
46XY gonadal dysgenesis
Turcot syndrome
Sturge-Weber syndrome
Bloom syndrome
Xeroderma pigmentosum
Hypogammaglobulinemia
IgA deficiency
Severe combined immunodeficiency
Total
No. ofentries:
162
135
90
71
20
7
6
3
3
2
2
2
1
l
509
Table II Total number of cancers and proportion with genetic
conditions
Number of Number with
Children genetic conditions %
Leukaemias 5,564 142 2.6
Lymphomas 1,781 17 1.0
Brain and spinal cord 3,872 79 2.0
Sympathetic 985 2 0.2
Nervous system
Retinoblastoma 436 162 37.2
Kidney 984 71 7.2
Liver 135 3 2.2
Bone 850 0 0.0
Soft tissue sarcoma 1,003 20 2.0
Gonadal and germ cell 430 3 0.7
Epithelial 524 10 1.9
Total 16,564 509 3.1
Genetic conditions listed are those that appear in Table I.
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Figure 1 Risk of acute leukaemia associated with Down syn-
drome. White bars represent acute non-lymphocytic leukaemia
and black bars represent acute lymphocytic leukaemia. Expected
numbers based on an incidence of Down syndrome of 1.15 per
1000 (Neilsen & Sillesen, 1975).
47,XY + 21/46,XO + 21 karyotype and testicular feminisa-
tion. One testicular teratoma was seen in a 14-year old boy.
Other cancers, including two gliomas and one fibrosarcoma,
were not seen more often than expected and have not been
included in the heritable fraction.
Neurofibromatosis was found in excess in children with
both acute lymphocytic and chronic myeloid leukaemia
(Table III). Both cases of Hodgkin's disease were of the
nodular sclerosis subtype. Sixty of 3872 (1.5%) children with
tumours of the brain and spinal cord had neurofibromatosis,
including 23.4% of malignant optic gliomas and 4.9% of
meningiomas. Two tumours of the sympathetic nervous
system, including one of the four recorded cases of malignant
pheochromocytoma, were seen with neurofibromatosis. Neur-
ofibromatosis was recorded in 12 of 16 cases of neurofi-
brosarcoma. For all cancers combined, the relative risk
associated with neurofibromatosis was 16.3 (95% CI, 13.1 to
20.0). There were an additional 24 patients registered for
whom only cafe au lait spots were recorded, including 15
with astrocytomas and five with other brain neoplasms.
These have not been included in the genetic total.
Tuberous sclerosis is estimated to affect one in 15,000
children in Great Britain (Hunt & Lindenbaum, 1987). The
relative risk of 18.1 for all types of cancer in these children
(95% CI, 11.1 to 28.0) could be accounted for by a 70-fold
increase in brain tumours and 50-fold risk for rhabdomyosar-
coma (Table IV). The two rhabdomyosarcomas involved the
cervix of a 12 year old female, and the kidney of a 14 year
old male.
Ninety-eight per cent of kidney neoplasms were Wilms'
tumours, and of these, 51 or 5.3% were bilateral. Bilateral
Wilms' appeared earlier than the unilateral form (median age
at diagnosis 19 months vs 38 months, P<0.01). The ma-
jority (82%) of bilateral Wilms' tumours presented synchro-
aIncluded in hereditary forms of Wilms' tumour are bilateral cases
and cases associated with aniridia or hemihypertrophy. bThese cases
include one thyroid carcinoma, one non-Hodgkin's lymphoma and one
hepatoblastoma and are distinct from cases associated with Wilms'
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Table III Cancers associated with neurofibromatosis
Observed Expected Relative risk
All leukaemia 7 1.85 3.8a
Acute lymphocytic 4 1.46 2.7
Chronic myelocytic leukaemia 3 0.04 71.4b
All lymphoma 3 0.59 5.1a
Hodgkin's disease 2 0.25 8.0a
Non-Hodgkin's lymphoma 1 0.30 3.4
All brain and spinal cord 60 1.29 46.5b
Ependymoma 1 0.15 6.6
Optic glioma 34 0.05 920b
Other astrocytoma 13 0.42 31.1b
Medulloblastoma 3 0.26 11.4a
Meningioma 3 0.02 155b
Other glioma 6 0.21 29.0b
All sympathetic 2 0.33 6.1a
Neuroblastoma 1 0.32 3.1
Pheochromocytoma 1 0.001 1000a
All soft tissue sarcoma 18 0.33 53.8b
Rhabdomyosarcoma 5 0.21 23.4b
Neurofibrosarcoma 12 0.005 goo0b
Other fibrosarcoma 1 0.05 20
All cancers 90 5.52 16.3b
Expected numbers of tumours based on an incidence of neurofi-
bromatosis of 1:3000 individuals (Crowe et al., 1956). Because of the
high proportions ofoptic gliomas, pheochromocytoma, meningiomas
and neurofibrosarcomas associated with neurofibromatosis the odds
ratio is used to approximate the relative risk. ap<0.05; bp<0.001
Table IV Cancers associated with tuberous sclerosis
Observed Expected Relative risk
Brain and spinal 18 0.26 69.7a
Astrocytoma 9 0.09 104a
Other glioma 6 0.04 150a
Other CNS 3 0.04 75a
Rhabdomyosarcoma 2 0.04 SOa
All cancers 20 1.1 18.1a
ap<0.01. Expected numbers of tumours based on an incidence of
tuberous sclerosis of 1: 15,000 individuals (Hunt & Lindenbaum, 1984).
nously; for the remaining nine bilateral tumours the interval
between diagnoses ranged from 4 to 88 months. Twelve cases
(1.2%) of Wilms' tumour occurred with aniridia (four with
bilateral tumours, eight with unilateral). Hemihypertrophy
appeared in two cases with aniridia and 12 additional cases
without aniridia. Four of the 12 cases of Wilms' tumour
associated with aniridia also had genital abnormalities.
Isolated genitourinary abnormalities, although not consi-
dered sufficient evidence of genetic predisposition, were seen
ten times more frequently among Wilms' tumour patients
(2.0%) than among patients with other tumours (0.2%).
Primary liver cell tumours accounted for less than 1% of
all cancers. Among 102 cases of hepatoblastoma there was
one infant with the Beckwith-Wiedemann syndrome. Of the
33 cases of liver carcinoma, one was associated with hypo-
gammaglobulinemia.
Less than 3% of the genetic cancers were attributable to
immunodeficiency (Table V). The risk for lymphoma among
children with ataxia-telangiectasia, based on a disease fre-
quency of one in 100,000 (Pippard et al., 1988) was 400 times
greater than in the general population. One child with skin
carcinoma and IgA deficiency was reported.
There were 11 cases of medullary thyroid carcinoma,
representing 17.2% ofchildhood thyroid cancers. Six of these
children were from families with multiple endocrine neoplasia
type 2, four of whom had features of the mucosal neuroma
syndrome.
Three other genetic conditions were included as underlying
causes of carcinomas (which represent 3.5% of all childhood
cancer): one child with hemihypertrophy and thyroid car-
cinoma; one with xeroderma pigmentosum and squamous
cell carcinoma of the orbit; and one with Turcot syndrome
and adenocarcinoma of the colon. In addition, malignant
germ cell tumours were recorded in two phenotypic females
with 46,XY gonadal dysgenesis.
Discussion
An early age of onset is one of the features that discriminate
between familial and sporadic cancer. We have estimated the
hereditary fraction of childhood cancers retrospectively from
information on genetic diagnoses in a large population-based
series of cancer cases, an approach that does not require
knowledge of gene frequencies add cancer penetrance. For
some cancer types the numbers of cases are insufficient to
estimate the effect of rare genetic traits with precision. The
proportion of cancers are due to inherited mutations may be
underestimated if documentation of constitutional abnor-
malities and other underlying conditions is incomplete. Regis-
try cases which are genetic by virtue of either family history,
chromosomal abnormalities or multiple primaries will have
been overlooked in the above analysis; we attempt to esti-
mate the size of these additional proportions from published
reports in the following discussion.
Genetic forms of retinoblastoma other than bilateral in-
clude unilateral familial tumours, unilateral tumours in per-
sons carrying 13q deletions and unilateral sporadic tumours
associated with new germ cell mutations which are not visible
cytogenetically. Tumours in the last category will not be
considered to be familial at the time of diagnosis, but will be
transmitted to 50% of the patient's children. Because the 13q
deletion is rarely transmitted (Motegi et al., 1983; Bunin et
al., 1989) the three subgroups of patients with unilateral
tumours can be considered as non-overlapping. Of 123 uni-
lateral cases in an American series, five were familial (4.1%)
and a further six cases carried deletions of 13q (4.9%) (Bunin
et al., 1989). Applying these rates to the 274 unilateral cases
in the Registry would yield 24.6 additional genetic cases. In
an earlier report of retinoblastoma patients treated in Britain
between 1950 and 1977, 44% of 882 children had either
bilateral disease or a positive family history (Draper et al.,
1986). Forty per cent of a series of 598 French patients were
hereditary by the same two criteria (Briard-Guillemot et al.,
1974). Retinoblastomas due to new mutations which are not
detected cytogenetically may be ascertained through their
offspring. Of 434 children of unilateral sporadic cases re-
ported to 1979, 24 were affected (reviewed by Vogel, 1979),
but none in a series of 94 more recently observed offspring
developed retinoblastoma (Hawkins et al., 1989). Assuming
90% penetrance, the combined recurrence risk of 4.5% im-
plies a hereditary fraction of 10.1% for this subgroup (95%
confidence interval, 6.7% to 15.1%). Adding 10% of the
non-familial, unilateral cases (436-162 - 11.2 = 263 cases)
to the total increases the genetic fraction of retinoblastoma
Table V Cancers associated with immunodeficiency states
Hodgkin's Non-Hodgkin's
Leukaemia disease lymphoma Other
n=2 n=2 n= 7 n=2
Ataxia-telangiectasia 0 2 5 0
Severe combined immunodeficiency 1 0 0 0
Wiskott-Aldrich 1 0 2 0
Hypogammaglobulinemia 0 0 0 1
IgA deficiency 0 0 0 1996 S.A. NAROD et al.
to 49% (Table VI). This estimate is larger than the figure of
40% often quoted, and the 44% figure from the earlier
Registry report (Draper et al., 1986) but we have extended
previous findings to include cases due to new mutations.
In the American National Wilms' Tumor Study, 37 of
3442 (1.1%) of children with Wilms' tumour had a positive
family history. (Breslow et al., 1988); 11% of all patients
could be classified as genetic because of one or more of
bilaterality (7.0% of the total); aniridia (0.8%) hemihyper-
trophy (3.3%) or family history. In a French series 13% of
298 patients were genetic by these criteria (Bonaitai-Pellie et
al., 1988). No recurrent cases were found among 179 (Li et
al., 1988) or 54 (Hawkins et al., 1989) children of unilateral
sporadic cases a finding inconsistent with a hereditary
fraction of greater than 3% for this subgroup (P = 0.05). The
evidence for a constitutional mutation in patients with bi-
lateral Wilms' tumour or with hemihypertrophy alone is less
than for bilateral retinoblastoma because few offspring of
these patients have been observed. Familial Wilms' tumour
and Wilms' tumour with aniridia combined yield a much
more conservative genetic proportion of 2.2%.
An analysis of 143 children with soft tissue sarcoma in the
Manchester Children's Tumour Registry revealed 11 children
with family histories suggestive of the Li-Fraumeni syndrome
(Birch et al., 1984). Two sarcomas occurred in siblings and
six patients (one with a sibling with an adrenocortical
tumour) had mothers with pre-menopausal or bilateral breast
cancer. A further two patients had siblings with astrocytoma
and one had a sibling with a Wilms' tumour. Of 73 patients
with osteosarcoma in the Manchester Registry, six mothers
had breast cancer, compared with 2.1 expected (P<0.05)
(Hartley et al., 1986). Barring chance association, four of the
tumours may be attributed to a variant of the Li-Fraumeni
syndrome. These proportions need to be confirmed in other
populations. Osteosarcomas also appear in families with
hereditary retinoblastoma, either as second primary tumours
or in individuals without prior disease. In a British study
6.0% of survivors of hereditary retinoblastoma had devel-
oped an osteosarcoma within 18 years of the original diag-
nosis (Draper et al., 1986).
Childhood adrenocortical carcinomas appear in families at
high risk for various neoplasms, including rhabdomyosar-
coma, brain tumours, breast cancer, and osteosarcoma (Mil-
ler, 1978) and are often followed by tumours at other sites
(Fraumeni, 1977; Levine 1978). Of thirty-three cases of child-
hood adrenocortical carcinoma in the Registry, three were
known to have a first-degree relative with rhabdoymosar-
coma (two siblings, one father) and two had second primary
neoplasms recorded. One girl diagnosed with adrenocortical
carcinoma at three months developed a breast sarcoma at
Table VI The estimated proportion of cancers with underlying genetic etiologies, incorporating family
history
Total no. ofcases
Condition with condition Per cent
Total leukaemia 142 2.6
Down syndrome 131 2.4
Neurofibromatosis 7 0.1
Deficiency 2 0.0
Others 2 0.0
Total lymphoma 17 1.0
Ataxia-telangiectasia 2 0.4
Neurofibromatosis 3 0.2
Wiskott-Aldrich syndrome 2 0.1
Others 7 0.3
Total brain and spinal cord 79 2.0
Neurofibromatosis 60 1.5
Tuberous sclerosis 18 0.5
Turcot syndrome 1 0.0
Total sympathetic 2 0.2
Neurofibromatosis 2 0.2
Total retinoblastoma 212.9 48.8
Bilateral retinoblastoma 162 37.1
Familial unilateral retinoblastoma 11.2 2.5
13q deletions, unilateral 13.4 3.1
Sporadic unilateral retinoblastoma 26.3 6.0
Total kidney 80.6 8.2
Bilateral Wilms' 51 5.2
Unilateral Wilms' with aniridia or hemihypertrophy 20 2.0
Familial Wilms' 9.6 1.0
Total liver 3 2.2
Total bone 44.7 5.7
Li-Fraumeni syndrome 38.5 4.5
Hereditary retinoblastoma 10.2 1.2
Total soft tissue sarcoma 97.2 9.7
Li-Fraumeni syndrome 77.2 7.7
Tuberous sclerosis 2 0.2
Neurofibromatosis 18 1.5
Total gonadal and germ cell 3 0.7
46XY gonadal dysgenesis 2 0.4
Down syndrome 1 0.2
Total epithelial 15 2.9
Multiple endocrine neoplasia type 2 6 1.1
Li-Fraumeni syndrome 5 1.0
Others 4 0.8
All cancers 696.4 4.2
Estimates with decimals incorporate information from published reports (see text). Integer estimates are
based on National Childhood Tumour Registry data only. The tumours associated with the Li-Fraumeni
syndrome intheepithelialcategoryareadrenocortical carcinomas. Nooverlapisassumed between thethree
subgroupsofunilateral retinoblastoma. Theestimatednumberofbonetumoursfollowingretinoblastomais
based on the derived mean ofthe incidence at 12 years (3.6%) and at 18 years (6.0%) post-treatment, from
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age 14. In another child, an osteosarcoma developed 10 years
after the initial diagnosis at age two. Two of these children
have been reported previously (Hartley et al., 1987). The two
second primaries which developed among 17 survivors of one
year or more represent a risk 167-fold greater than expected.
When the familial proportions of childhood cancers from
the above series are incorporated, a more complete picture of
the total hereditary pattern emerges (Table VI). We estimate
that a total fo 4.2% of childhood cancer cases have a genetic
basis; the largest contributions come from Down syndrome
(0.8%) the Li-Fraumeni syndrome (0.7%) neurofibromatosis
(0.5%) and tuberous sclerosis (0.1%). These probably repre-
sent minimum estimates of the fraction of cases due to sihgle
gene disorders because of under-reporting of genetic condi-
tions by the contributing physicians. The proportions of
children with a positive family history are also likely to be
low in many published studies because of incomplete ascer-
tainment and because cases are often reported before the
siblings have completed the period of risk. On the other
hand, reports from the literature may lead to over-estimates
of the familial proportions if there is a tendency to selectively
publish positive data.
For the other childhood tumour types the risk to relatives
is small. Family aggregation in Hodgkin's disease may be due
in part to shared HLA types (Hors et al., 1985) and favours
a multifactorial pattern of inheritance. Siblings of Hodgkin's
disease patients have an increased risk 7-fold (Grufferman et
al., 1977) or greater (Hafez et al., 1985a), but because of the
rarity of Hodgkin's disease the size of the actual increase is
small and risks are not specifically calculated for children.
Acute leukaemia in siblings has also been documented (Mil-
ler, 1963; Draper et al., 1977; Hafez et al., 1985b), especially
among younger cases.
Family clusters of neuroblastoma have been reported
(Chatten & Voorhess, 1967; Pegelow et al., 1975) but there is
little information available from extensive patient series. Two
familial cases were observed among 60 neuroblastoma cases
treated at the M.D. Anderson Hospital, Houston (Knudson
& Strong, 1972) and one of 246 children with neuroblastoma
registered in Denmark from 1943-1980 had a positive family
history (Carlsen, 1986). In other studies familial cases were
not seen (Kramer et al., 1987). The total hereditary fraction
of neuroblastoma is probably less than 1%. None of a total
of 48 children ofapparently sporadic cases developed neuro-
blastoma in three follow-up series (Li & Jaffe 1974; Bundey
& Evans 1982; Hawkins et al., 1989).
Although family history is an established risk factor for
adult testicular tumours (Dieckmann et al., 1987), there is
little evidence for a familial predisposition in children. In a
recent review of 82 reported family occurrences the only
childhood tumours were two seminomas in brothers aged 13
and 14 (Dieckmann et al., 1987). Seminomas figured in 66 of
the 82 affected first degree relative pairs, but this subtype
represents only two per cent of childhood testicular cancer
(Li & Fraumeni, 1972). More common childhood forms in-
clude embryonal carcinoma and teratocarcinoma (Exelby,
1980). In an American hospital-based series, none of 70
children with testicular tumours had a positive family history
noted in the chart (Li & Fraumeni, 1972). None of the
testicular tumours in the Registry were bilateral.
Malignant melanoma may cluster in families, and perhaps
10% of cases are the expression of the dysplastic nevus
syndrome (Greene et al., 1983). As younger cases are more
likely to be familial, it is surprising that none of the 78
children reported by Bader et al. (1985) or 27 children pres-
enting with malignant melanoma in St Judes Hospital, Bos-
ton had affected relatives (Pratt et al., 1988). Information on
associated conditions was seldom available for children with
skin tumours in the Registry.
Excluding the bilateral tumours, Down syndrome and
neurofibromatosis together account for three-fourths of the
tumours in the Registry for which genetic syndromes are
recorded. In a series of 5,406 children with acute childhood
leukaemia entering clinical trials, 2.1% had Down syndrome
- equivalent to a relative risk of 18.5 (Robison et al., 1984).
This figure is similar to the Registry figure (2.3%) and to
others (Stewart et al., 1958; Kardos et al., 1983) but is
greater than the 1.1% observed in surveys in Boston 1947-
-1965 (Fraumeni et al., 1971) and Manchester 1954-1968
(Evans & Steward, 1972). The increase may reflect improved
survival of children with Down syndrome, recently estimated
to be 76.6% to age 15 in British Columbia (Baird & Sadov-
nick, 1989), as compared with 48% survival to age 3 at the
time of the Manchester survey (Evans & Steward, 1972).
Although the finding of a single case of malignant tes-
ticular teratoma in a 14 year-old boy with Down syndrome is
not statistically significant, it confirms other reports (Miller,
1970; Dexeus et al., 1988; Baird & Sadovnick, 1988), includ-
ing that of Mann et al. (1989) who found two children with
Down syndrome among 61 cases of childhood testicular
tumours when 0.07 cases were expected (P<0.01).
The malignant complications of neurofibromatosis are well
known (Hope & Mulvihill, 1981). Of a total of 401 children
hospitalised with neurofibromatosis in the five series sum-
marised by Hope & Mulvihill (1981) and more recently (Blatt
et al., 1986) malignant tumours were identified in 7.2% -
most commonly, brain (3.0%) neurofibrosarcoma (2.5%),
and leukaemia (1.0%). An additional 10% of children had
optic gliomas, but these include asymptomatic tumours dis-
covered by routine screening. Although rhabdomyosarcoma
was not reported in these series, five of 84 children with
rhabdomyosarcoma reported by McKeen et al. (1978) and
four of 115 children reported by Hartley et al. (1988) had a
concomitant diagnosis of neurofibromatosis. Our estimate of
0.8% for rhabdomyosarcoma may reflect under-reporting,
but for other sites in our series the documentation rate was
high - our figure of 75% for neurofibrosarcoma agrees with
the earlier estimates of Chabalko et al. (1974) and Storm et
al. (1980). Higher attributable fractions than those seen in
the Registry have also been reported by Merten et al. (1974)
for childhood meningioma (23%) and by Hoyt & Baghdas-
sarian (1969) for optic nerve gliomas (58%). Bader et al.
(1980) evaluated 4,900 successive cases of childhood cancer
for underlying genetic conditions and found that
neurofibromatosis was mentioned in 0.8% of the total. We
estimate the fraction of childhood cancer due to neuro-
fibromatosis to be 0.5% which includes 1.8% of all soft
tissue sarcomas and 1.5% of brain tumours.
Congenital immunodeficiencies which predispose to lym-
phoma and leukaemia in children include ataxia-telangiec-
tasia, the Wiskott-Aldrich syndrome, the Chediak-Higashi
syndrome, congenital agamaglobulinemia and the X-linked
lymphoproliferative syndrome (Filipovich et al., 1985; Purtilo
et al., 1975). Thirteen per cent of children with the recessive
degenerative disease ataxia-telangiectasia, which has an inci-
dence of one in 100,000 (Pippard et al., 1988), will develop
cancer by age 15 (60% of these are lymphomas and 27%
leukaemia) (Morrel et al., 1986). Fifty per cent of the cases of
leukaemia reported to the Immunodeficiency Cancer Registry
from 1973-1984 were associated with to ataxia-telangiectasia
(Filipovich et al., 1985) but ages of diagnosis were not given.
Ataxia-telangiectasia was not associated with childhood leu-
kaemia in the present study.
The reasons for the documented association of congenital
defects and several cancers are not clear. In rare cases a
prenatal exposure has been implicated (e.g. diethylstilbes-
terol, genital malformations and vaginal adenocarcinomas;
Herbst et al., 1975). In some, malformations and childhood
neoplasms may be the various expressions of a single mutant
gene, and in others, chromosomes may be deleted for con-
tiguous genes with discrete effects. In the majority ofchildren
with Wilms' tumour and aniridia a deletion of 1 p13 is
detectable (Riccardi et al., 1980). Other cases of Wilms' may
be associated with hemihypertrophy, genitourinary abnor-
malities, (Breslow et al., 1988) or cardiac septal defects
(Stiller et al., 1987) and may reflect abnormal embryonic
development. Renal abnormalities have been documented in
children with acute lymphoblastic leukaemia (Robison et al.,
1982) and hepatoblastoma is associated with hemihyper-
trophy (Fraumeni et al., 1968) and familial polyposis (King-998 S.A. NAROD et al.
ston et al., 1983; Li et al., 1987). Defects of the neural tube,
sacrum and pelvis are more common in children with germ
cell tumours (Fraumeni et al., 1973; Birch et al., 1982).
If genetic counselling is to be applied to the prevention of
cancer, it is first necessary to identify the individual at risk -
but a positive family history will be seen in only a fraction of
genetic cases. The vast majority of occurrences of Down
syndrome are sporadic. Three quarters of patients with
genetic retinoblastoma (Bunin et al., 1989; Sanders et al.,
1988) and 89% of bilateral Wilms' tumour patients (Breslow
et al., 1988) occur in families with no other members
affected. One-half of neurofibromatosis cases are the result of
new mutations (Crowe et al., 1956) and as average family
size becomes smaller, the majority of new cases of recessive
disease will be isolated as well.
The diagnosis of a few cancer syndromes is now possible
by polymorphic DNA markers, including retinoblastoma
(Wiggs et al., 1988) and multiple endocrine neoplasia (type
2a (Sobol et al., 1989)) or direct analysis of mutations
(Yandell et al., 1989) and early identification and surgery
may benefit the individual at-risk. Prophylactic surgery is
also advised for the rare female patient with gonadal
dysgenesis who carries Y chromosome material. Although
the recurrence risk in neuroblastoma has not been precisely
established, screening of close relatives of cases by urinary
catecholamines is probably justified.
The results of this survey and literature review suggest that
roughly 4% of childhood cancers are directly attributable to
genetic conditions. Because an underlying syndrome or a
positive family history may be unrecognised or go unre-
ported, this estimate is likely to be a minimum. Variations in
incidence between ethnic groups for several tumour types and
a lack of known environmental determinants suggest that the
role of hereditary factors in childhood cancer may be con-
siderably greater.
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nucleus, which could be diffuse or dotted (Figure 4A). This nuclear
staining is unexplained. Results with both IGF-I antisera were
similar. Staining intensities were high in the cellular compartments
ofmyometrium and leiomyoma and lower in the cellular compart-
ments ofmostleiomyosarcomas (Figure 3B), representing asignif-
icantly asymmetrical distribution. Tissue concentrations of IGF-I,
as determined by a radioimmunoassay, are summarized in Figure
3A. Mean IGF-I concentration in leiomyomas was significantly
B higherthan in myometrium (not observed with immunohistochem-
emerges fromsmoothmusclecell. Thesignalistry). The variance of values in both groups of leiomyosarcomas
was too high to detect significant differences.
There is an inconsistency between changes in IGF-I levels as
detected with radioimmunoassay and with imnmunohistochemistry.
This may result from the fact that total tissue IGF-I concentrations
(radioimmunoassay) may be biased by the ratio of compartments
with high IGF-I contents (nuclei, cytoplasm) to those with low
IGF-I contents (extracellular compartment). This ratio varies
considerably between the different categories of smooth muscle
tissues. Immunohistochemical semiquantification was restricted to
the cellular compartments. Finally, some variation in loss of
unbound IGFs during immunohistochemical processing cannot be
excluded.
IGF-II immunostaining was diffuse over both smooth muscle
and stromal cells in myometrium, leiomyoma andleiomyosarcoma
(Figure 4B) with similar staining intensities in the cellular
compartments of the four categories of smooth muscle tissues
(Figure 3B). The peptide was predominantly found in the cyto-
C plasm and seemed to be concentrated in an area closely associated
with the nucleus. Results with all three IGF-ll antisera were
similar, apart from a more prominent detection of perinuclear
concentration with the no. 12/2378 antiserum. IGF-il peptide
.~~.levels(RIA,)werehigherinleiomyosarcomasthaninmyometrium
~~ .2 but, because of ahigh variance in low-grade leiomyosarcomas
the small sample size of intermediate-high-grade leiomyosar-
comas, this has no statistical significance.
Diffuse type I IGFreceptorimmunostaining was observed in the
cytoplasm of smooth muscle cells in all smooth muscle tissues
(Figure 4C), with higher intensity in leiomyomas than in
myometrium and leiomyosarcomas (Figure 3B). Immunostaining
for the type II IGF receptor revealed positive staining, also in
smooth muscle cells. Diffuse immunostaining was found over the
k ~ ~~~~ 4 4 ~~~~~cytoplasm (Figure 4D). Staining intensity was similar in
myometrium and leiomyoma, but there was a lower staining inten-
sity in most leiomyosarcomas (Figure 3B). IGFBP-3 was visual-
* j .~~~.~ *i~~ L~~4 ~ ized by immunohistochemistry in the cytoplasm of smooth muscle
Figujre 2 Insitu hybridlization forl'IGF lImmRNA ilutaigta h inl cells (Figzure 4E), with higyher intensity in myometrium and